Description
Release form
Tablets.
40 pcs packaging
Pharmacological action
An agent that stimulates gastrointestinal motility. Itopride enhances the propulsive motility of the gastrointestinal tract due to antagonism with respect to dopamine D2 receptors and dose-dependent inhibition of acetylcholinesterase activity. Itopride activates the release of acetylcholine and inhibits its destruction. Itopride has a specific effect on the upper gastrointestinal tract, accelerates the transit through the stomach and improves its emptying. It also has an antiemetic effect due to interaction with D2 receptors located in the trigger zone. Itopride caused a dose-dependent inhibition of apomorphine-induced vomiting. Does not affect the serum level of gastrin.
Pharmacokinetics
Quickly and well absorbed in the digestive tract. Relative bioavailability is 60%. Сmax – 0.28 μ / ml, TCmax – 0.5-0.75 hours after taking 50 mg of the drug. With repeated administration of 50-200 mg 3 times a day for 7 days, the pharmacokinetics is linear in nature, the cumulation is minimal. Communication with proteins – 96% (mainly with albumin with alpha1-acid glycoprotein – less than 15%). It is distributed in the kidneys, small intestine, liver, adrenal glands, and stomach. Distribution volume – 6.1 l / kg. In therapeutic doses, it slightly penetrates the brain and spinal cord, into breast milk. It is metabolized in the liver under the influence of flavin-dependent monooxygenase. 3 metabolites have been identified, only one of them exhibits insignificant activity (2-3% of the activity of itopride), which does not have pharmacological significance. It is excreted by the kidneys. T1 / 2 – 6 hours, in patients with trimethylaminuria, T1 / 2 increases.
Indications
Symptomatic treatment of functional non-ulcer dyspepsia (chronic gastritis), in particular, relief of bloating (flatulence), pain or discomfort in the epigastric region (gastralgia), anorexia, heartburn, nausea, vomiting.
Contraindications
Hypersensitivity to itopride or any auxiliary component of the drug, gastrointestinal bleeding, mechanical obstruction and perforation of the gastrointestinal tract, children under 16 years of age, pregnancy and lactation (breastfeeding).
Pregnancy and lactation
Pregnancy and lactation (breastfeeding) are contraindicated.
Special instructions
Caution is advised to use itoprid in patients for which the appearance of cholinergic adverse reactions (associated with an increase in the action of acetylcholine under the influence of itopride) can worsen the course of the underlying disease.
Composition
Active ingredient: Itoprida hydrochloride 50.0 mg.
Dosage and administration
Take orally 50 mg 3 times / day. The recommended daily dose is 150 mg. The indicated dose can be reduced taking into account the age of the patient.
Side effects
From the hematopoietic system: leukopenia, thrombocytopenia.
From the endocrine system: increased levels of prolactin, gynecomastia.
From the side of the central nervous system: dizziness, headache, tremor.
From the digestive system: diarrhea, constipation, abdominal pain, increased salivation, nausea, jaundice.
Allergic reactions: flushing of the skin, pruritus, rash, anaphylaxis.
Drug Interactions
Accelerates the absorption of other drugs. The prokinetic effect of the drug does not change under the influence of antiulcer drugs (cimetidine, ranitidine, teprenone, cetraxate). Cholinergic drugs weaken the effect of the drug.
Deystvuyuschee substance
Itoprid
Prescription terms from
pharmacies Prescription
dosage form
tablets
Obolensky AF Russian
